Dabrafenib/Trametinib Combination Receives FDA Approval for BRAF V600E–Mutated Solid Tumors

Recommended

FDA Approves Ventana MMR RxDx Panel to Identify Patients With dMMR Solid Tumors and pMMR Endometrial Cancer Eligible for Treatment With Pembrolizumab

FDA Approves Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer

FDA Approves First Targeted Therapy for HER2-Low Breast Cancer

FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumors

FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib

A Framework for Assessing the Impact of Accelerated Approval

FDA Approves Lisocabtagene Maraleucel for the Second-Line Treatment of Large B-Cell Lymphoma

Dabrafenib/Trametinib Combination Receives FDA Approval for BRAF V600E–Mutated Solid Tumors

header-info

Jun, 23, 2022

The U.S. Food and Drug Administration (FDA) granted accelerated approval for dabrafenib (Tafinlar) plus trametinib (Mekinist) for the treatment of adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors...